Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL27955723 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL8919110 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Ornithine Aketoglutarate SCHEMBL361184 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL28321586 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL755884 | 1.00 | GSR (0.69) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL14656074 | 0.98 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Aspartic Acid SCHEMBL27858630 | 0.98 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Ornithine SCHEMBL14656075 | 0.98 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL1425215 | 0.94 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL1425217 | 0.94 | GSR (0.80) | GSRCYP1A2GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 580 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4731232-A1 | POROUS CARBON PARTICLES FOR USE IN THERAPY | UCL Business Ltd (GB) | 2026-04-29 | — | — | EP | claimed |
| CN-120034274-A | Multichannel signal real-time monitoring access system capable of flexibly expanding scale | 成都立思方信息技术有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119804682-A | Analysis method for detecting related substances in ornithine aspartate | 远大医药（中国）有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119413935-A | Method for detecting ornithine aspartate isomer | 远大医药（中国）有限公司 | 2025-02-11 | — | — | CN | claimed |
| WO-2024261472-A1 | POROUS CARBON PARTICLES FOR USE IN THERAPY | YAQRIT LIMITED (GB) | 2024-12-26 | — | — | WO | claimed |
| US-12144848-B2 | Arginine depletion therapy for treatment of GAMT deficiency | IMMEDICA PHARMA AB (SE) | 2024-11-19 | — | — | US | claimed |
| WO-2024194181-A1 | NH3 SCAVENGER FOR USE IN THE TREATMENT OF MOBILITY DISABILITY IN A POST-STROKE PATIENT | Merz Therapeutics GmbH (DE) | 2024-09-26 | — | — | WO | claimed |
| US-20240285567-A1 | COMPOSITIONS AND METHODS FOR IMPROVING KIDNEY FUNCTION | CROSS III WILLIAM H (US) | 2024-08-29 | — | — | US | claimed |
| US-20110182858-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | MADAUS GMBH (DE) | 2011-07-28 | — | — | US | claimed |
| US-20110117194-A1 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER | HANALL BIOPHARMA CO., LTD. (KR) | 2011-05-19 | — | — | US | claimed |
| EP-2281557-A2 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER | HanAll Biopharma Co., Ltd. (KR) | 2011-02-09 | — | — | EP | claimed |
| CN-101843587-A | Preparation method of ornithine aspartate powder injection for injection | HUBEI HOPE PHARMACEUTICAL CO LTD | 2010-09-29 | — | — | CN | claimed |
| EP-2219642-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | Madaus GmbH (DE) | 2010-08-25 | — | — | EP | claimed |
| WO-2009062737-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | MADAUS GMBH (DE) | 2009-05-22 | — | — | WO | claimed |
| EP-1044672-B1 | Water-in-oil emulsified cosmetic | SHISEIDO CO LTD (JP) | 2007-03-07 | — | — | EP | claimed |
| EP-0477991-B1 | Process for producing crystals of salt of acidic amino acid and basic amino acid | KYOWA HAKKO KOGYO KK (JP) | 1994-12-28 | — | — | EP | claimed |
| US-5227007-A | PROCESS FOR PRODUCING CRYSTALS OF SALT OF ACIDIC AMINO ACID AND BASIC AMINO ACID | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-07-13 | — | — | US | claimed |
| EP-0477991-A1 | Process for producing crystals of salt of acidic amino acid and basic amino acid | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-04-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182858-A1 | SILIBININ COMPONENT FOR THE TREATMENT OF HEPATITIS | VIP, HAVCR2, PYGL | GSR 3580/4885CYP1A2 2286/4885GRM8 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.